Candel Therapeutics progresses Phase 3 trial for treatment in high-risk localized prostate cancer

Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-EndПодробнее

Breakthrough in Prostate Cancer: CAN-2409's Game-Changing Phase 3 ResultsПодробнее

Phase 3 trial results suggest potential new treatment approach for prostate cancerПодробнее

FLAME trialПодробнее

New Concepts in ADTПодробнее

ProtecT Trial OverviewПодробнее

Rationale of Phase III PCS5 trial of hypofractionated radiotherapy for prostate cancerПодробнее

Candel Therapeutics advances Phase 2b trial for innovative prostate cancer treatmentПодробнее

Paul Peter Tak, CEO of Candel Therapeutics, Discusses the Treatment of GlioblastomaПодробнее

ProtecT trial: a battle between three treatments for patients with localized prostate cancerПодробнее

Candel Therapeutics presents preclinical data with CAN-3110 in Melanoma model at SITC annual MeetingПодробнее

Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | Learn Clinical TrialsПодробнее

ImmunoTherapy - Prostvac phase III Clinical Study for advanced Prostate CancerПодробнее

Doctor Explains the ProtecT TrialПодробнее

Prostate Cancer Immunotherapy TrialsПодробнее

Candel Therapeutics stock up 172% after Phase III prostate cancer successПодробнее

Addressing the issues faced in the ProtecT trial for patients with localized prostate cancerПодробнее

Candel Therapeutics (NASDAQ: $CADL): Revolutionizing Glioma Treatment and Redefining HopeПодробнее

Emerging Strategies to Reverse Prostate Cancer Therapeutic ResistanceПодробнее